id: NEW:ketamine_assisted_therapy_access_to_alcohol_use_disorder
name: Ketamine-Assisted Therapy Access â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:ketamine_assisted_therapy_access
  node_name: Ketamine-Assisted Therapy Access
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Ketamine administration modulates glutamatergic neurotransmission via NMDA receptor antagonism'
- 'Step 2: Glutamatergic modulation reduces alcohol withdrawal symptoms and craving'
- 'Step 3: Reduced withdrawal severity decreases benzodiazepine requirements for detoxification'
- 'Step 4: Improved withdrawal management supports sustained abstinence from alcohol'
evidence:
  quality_rating: B
  n_studies: 6
  primary_citation: 'Reinhard Janssen-Aguilar et al. 2025. "Role of ketamine in the treatment of substance
    use disorders: A systematic review.." https://doi.org/10.1016/j.josat.2025.209705'
  supporting_citations:
  - Additional citations require full-text access - systematic review included 6 studies on AUD
  - Studies examined ketamine doses ranging from 0.11 mg/kg to 2.0 mg/kg
  - Study endpoints ranged from less than a day to two years
  doi: 10.1016/j.josat.2025.209705
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Ketamine, an NMDA receptor antagonist, reduces alcohol withdrawal symptoms and benzodiazepine
  requirements in patients with Alcohol Use Disorder through glutamatergic neurotransmission modulation.
  This systematic review found evidence of short-term benefits, though evidence is limited by small sample
  sizes and lack of randomized trials.
quantitative_effects:
  sample_size: 551
moderators:
- name: psychotherapy_combination
  direction: strengthens
  strength: moderate
  description: 50% of studies combined ketamine with psychotherapy, which may enhance treatment effects
    compared to ketamine alone
- name: ketamine_dose
  direction: strengthens
  strength: moderate
  description: Dose ranges varied from 0.11 mg/kg to 2.0 mg/kg; optimal dosing remains unclear
structural_competency:
  equity_implications: Access to ketamine-assisted therapy represents a structural healthcare access issue.
    Treatment availability may be limited by regulatory barriers, cost, specialist availability, and healthcare
    system capacity. Equitable access to novel SUD treatments is essential to address alcohol-related
    health disparities, particularly in underserved communities with limited addiction medicine resources.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.948769'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
